A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

James R. Berenson; James D. Hilger; Ori Yellin; Ralph V. Boccia; Jeffrey Matous; Kenneth Dressler; Hassan H. Ghazal; Saad Jamshed; Edwin C. Kingsley; Wael A. Harb; Stephen J. Noga; Youram Nassir; Regina A. Swift; Robert Vescio

doi:10.1007/S00277-013-1910-2

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

James R. Berenson
, James D. Hilger
, Ori Yellin
, Ralph V. Boccia
, Jeffrey Matous
, Kenneth Dressler
, Hassan H. Ghazal
, Saad Jamshed
, Edwin C. Kingsley
, Wael A. Harb
, Stephen J. Noga
, Youram Nassir
, Regina A. Swift
, Robert Vescio

Oncotherapeutics
Oncotherapeutics, Los Angeles, USA
Center for Cancer and Blood Disorders, Bethesda, USA
Colorado Blood Cancer Institute, Denver, USA
St. Vincent’s Medical Center, Bridgeport, USA
Kentucky Cancer Clinic, Hazard, USA
University of Rochester
Comprehensive Cancer Centers of Nevada, Las Vegas, USA
Horizon Oncology Research, Inc, Lafayette, USA
Harry and Jeanette Weinberg Cancer Institute, Baltimore, USA
James R. Berenson, MD, Inc, Los Angeles, USA
Cedars-Sinai Medical Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Hematology
Volume	93
Issue number	1
DOIs	https://doi.org/10.1007/S00277-013-1910-2
State	Published - Jan 1 2014
Externally published	Yes

Disciplines

Pharmacology
Medicine and Health Sciences
Oncology
Hematology
Internal Medicine

Access to Document

10.1007/S00277-013-1910-2License: Unspecified

Cite this

Berenson, J. R., Hilger, J. D., Yellin, O., Boccia, R. V., Matous, J., Dressler, K., Ghazal, H. H., Jamshed, S., Kingsley, E. C., Harb, W. A., Noga, S. J., Nassir, Y., Swift, R. A., & Vescio, R. (2014). A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology, 93(1). https://doi.org/10.1007/S00277-013-1910-2

Berenson, JR, Hilger, JD, Yellin, O, Boccia, RV, Matous, J, Dressler, K, Ghazal, HH, Jamshed, S, Kingsley, EC, Harb, WA, Noga, SJ, Nassir, Y, Swift, RA & Vescio, R 2014, 'A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.', Annals of Hematology, vol. 93, no. 1. https://doi.org/10.1007/S00277-013-1910-2

@article{ceb9da84ec7b41299a4df2653f5fbc2d,

title = "A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.",

author = "Berenson, \{James R.\} and Hilger, \{James D.\} and Ori Yellin and Boccia, \{Ralph V.\} and Jeffrey Matous and Kenneth Dressler and Ghazal, \{Hassan H.\} and Saad Jamshed and Kingsley, \{Edwin C.\} and Harb, \{Wael A.\} and Noga, \{Stephen J.\} and Youram Nassir and Swift, \{Regina A.\} and Robert Vescio",

note = "Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently exhibiting synergy with the alkylating agent melphalan (Sanchez et al., Leuk Res 35(3):373-379, 2011). This phase 1/2 trial investigated the safety and efficacy of panobinostat in combination with melphalan for relapsed/refractory multiple myeloma patients.",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/S00277-013-1910-2",

language = "American English",

volume = "93",

journal = "Annals of Hematology",

issn = "1432-0584",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

AU - Berenson, James R.

AU - Hilger, James D.

AU - Yellin, Ori

AU - Boccia, Ralph V.

AU - Matous, Jeffrey

AU - Dressler, Kenneth

AU - Ghazal, Hassan H.

AU - Jamshed, Saad

AU - Kingsley, Edwin C.

AU - Harb, Wael A.

AU - Noga, Stephen J.

AU - Nassir, Youram

AU - Swift, Regina A.

AU - Vescio, Robert

N1 - Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently exhibiting synergy with the alkylating agent melphalan (Sanchez et al., Leuk Res 35(3):373-379, 2011). This phase 1/2 trial investigated the safety and efficacy of panobinostat in combination with melphalan for relapsed/refractory multiple myeloma patients.

PY - 2014/1/1

Y1 - 2014/1/1

UR - https://link.springer.com/article/10.1007%2Fs00277-013-1910-2

U2 - 10.1007/S00277-013-1910-2

DO - 10.1007/S00277-013-1910-2

M3 - Article

SN - 1432-0584

VL - 93

JO - Annals of Hematology

JF - Annals of Hematology

IS - 1

ER -

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Disciplines

Access to Document

Other files and links

Cite this